The metabolic research peptides scientists actually cite

GLP-1, GIP and triple-agonist reference compounds, supplied as lyophilized powder and paired with plain-English, PubMed-cited education. Built for serious laboratory and educational research.

Start your order →

✔ Research-grade compounds ✔ For laboratory use only ✔ PubMed-cited education

The science in plain English

GLP-1, GIP & the agonist ladder

Many of the most-discussed metabolic peptides are receptor agonists, molecules that switch on a receptor pathway. The number of pathways a compound engages is one of the key differences researchers study. In published research, engaging additional pathways has generally been associated with broader metabolic effects in study models.

Semaglutide

Single agonist
1 pathway · GLP-1

Tirzepatide

Dual agonist
2 pathways · GLP-1 + GIP

Retatrutide

Triple agonist
3 pathways · GLP-1 + GIP + glucagon

As you climb the ladder from one pathway to three, the compound engages more of the metabolic signalling researchers are interested in. That is why the triple-agonist Retatrutide draws so much research attention right now.

Featured compounds

The two most-referenced BURN compounds

Both supplied as lyophilized powder with a handling guide. For laboratory and educational research only.

Triple agonist

Retatrutide

GLP-1 + GIP + glucagon · the most-discussed compound in current metabolic research. Earlier-stage evidence base. Lyophilized powder.

From $140 research use only Order →

Dual agonist

Tirzepatide

GLP-1 + GIP · the established dual-agonist benchmark in metabolic research, with a deeper published evidence base. Lyophilized powder.

From $130 research use only Order →

🔬

Research use onlySupplied for laboratory and educational research. Not for human or veterinary use.

🧪

Third-party-tested handlingSourcing and storage standards documented for transparency.

❄️

Cold-chain handlingLyophilized material held dry and cold through fulfillment.

📦

Ships from the USATracked, protected packaging with order updates.

Cited education

Every claim points back to the literature

We do not publish efficacy claims. We point you to the published research so you can evaluate the evidence yourself.

Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity · A Phase 2 Trial. N Engl J Med. doi:10.1056/NEJMoa2301972
Sanyal AJ, et al. (2024). Retatrutide for MASLD: a randomized phase 2a trial. Nat Med. doi:10.1038/s41591-024-03018-2
Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. doi:10.1056/NEJMoa2206038

Reference metadata sourced via PubMed. Citations describe published research in study models and are not claims about these products. For laboratory and educational research only.

Get the free BioRegen Research Reference Guide

Compound reference tables, reconstitution math, storage, and curated citations for the BURN line. Join the research list for RESEARCH10 (10% off your first order), new-compound alerts, and member-only promos.

Ready when you are

Start your BURN research order

One fast page. Default Retatrutide 10mg, change it in the cart. Secure checkout with the research-use attestation built in.

Go to express checkout →

For laboratory and educational research only. Not approved for human or veterinary use. Nothing here is medical advice.